Shares of Bausch Health Companies Inc (NYSE:BHC) have been assigned a consensus rating of “Buy” from the nineteen ratings firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $30.99.
A number of equities analysts have commented on the stock. Piper Jaffray Companies set a $29.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a research note on Tuesday, June 11th. Mizuho set a $45.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a research note on Thursday, June 20th. Zacks Investment Research raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research note on Tuesday, May 21st. Guggenheim assumed coverage on shares of Bausch Health Companies in a research note on Thursday. They set a “buy” rating and a $30.00 target price on the stock. Finally, Wolfe Research assumed coverage on shares of Bausch Health Companies in a research note on Friday, July 19th. They set an “outperform” rating and a $31.00 target price on the stock.
BHC stock traded up $0.67 during trading on Thursday, reaching $23.76. 2,064,458 shares of the stock were exchanged, compared to its average volume of 3,782,748. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 8.94. The business has a 50 day moving average price of $22.34 and a 200-day moving average price of $23.49. Bausch Health Companies has a 1 year low of $17.20 and a 1 year high of $28.45. The firm has a market capitalization of $7.77 billion, a price-to-earnings ratio of 5.91, a P/E/G ratio of 0.26 and a beta of 0.80.
Bausch Health Companies (NYSE:BHC) last issued its earnings results on Tuesday, August 6th. The company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.03). Bausch Health Companies had a positive return on equity of 52.12% and a negative net margin of 10.88%. The firm had revenue of $2.15 billion for the quarter, compared to analysts’ expectations of $2.15 billion. During the same period last year, the firm earned $0.93 earnings per share. Bausch Health Companies’s revenue for the quarter was up 1.1% on a year-over-year basis. On average, research analysts anticipate that Bausch Health Companies will post 4.24 EPS for the current year.
In other Bausch Health Companies news, insider William D. Humphries acquired 30,703 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $21.18 per share, for a total transaction of $650,289.54. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Christina Ackermann sold 3,418 shares of Bausch Health Companies stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $22.45, for a total transaction of $76,734.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,159 shares of company stock valued at $410,355. Company insiders own 11.87% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Citizens Financial Group Inc RI acquired a new position in shares of Bausch Health Companies in the second quarter valued at approximately $28,000. Investors Research Corp grew its holdings in shares of Bausch Health Companies by 85.7% in the second quarter. Investors Research Corp now owns 1,300 shares of the company’s stock valued at $33,000 after purchasing an additional 600 shares in the last quarter. Providence Capital Advisors LLC acquired a new position in shares of Bausch Health Companies in the first quarter valued at approximately $49,000. Asset Planning Services Ltd. acquired a new position in shares of Bausch Health Companies in the second quarter valued at approximately $55,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in shares of Bausch Health Companies in the second quarter valued at approximately $58,000. Hedge funds and other institutional investors own 56.06% of the company’s stock.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Featured Story: Why do companies pay special dividends?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.